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A B S T R A C T
The virtual crossmatch, which is based on single antigen bead technology, is used in the prediction of crossmatch
results. However, this assay differs in sensitivity and specificity from crossmatch methods. In our study, the
results of physical crossmatches, performed with three different methods, were assessed against virtual cross-
match results. The aim was to determine the potential cut-off values for donor specific antibodies (DSA) that
would predict the crossmatch results obtained by different methods. The results of different crossmatch tech-
niques were correlated with the virtual crossmatch. The receiver operating characteristic (ROC) analysis re-
vealed the Flow cytometric crossmatch (FCXM) and Luminex crossmatch (LXM) to be the most accurate, with
area under curve (AUC) values of 0.861 and 0.805, respectively. While we found that the virtual crossmatch
correlated well with all the crossmatch results, FCXM produced the best results (83% of the DSA detected). LXM
outperformed the other tests in terms of the accuracy in separating class II DSA.
1. Introduction
The relevance of preformed human leukocyte antigen (HLA) anti-
bodies in the context of transplantation was discovered in the 1960s
[1]. Antibodies detected by Complement-dependent cytotoxicity (CDC)
have the capacity to destroy donor cells via complement-mediated cy-
totoxicity. The fact that these antibodies have a clear effect on the cells
attests to the clinical relevance of this assay for both screening and
crossmatching [2]. However, accurate identification with CDC is pro-
blematic and the method is also very laborious. Innovations in com-
mercial HLA antibody screening kits utilizing bead array technology
have enabled the determination of antibody specificities with high ac-
curacy and sensitivity [3,4]. This technology is now widely used and
has replaced HLA antibody screening with the CDC method in many
laboratories. The development of crossmatch techniques, however, has
not made similar progress and consequently there are still many dif-
ferent crossmatch techniques in use today. This has led to a situation
where crossmatching and screening are based on completely different
technologies, quite often not even measuring the same variable.
As the main idea of a screening program is to predict crossmatches
that would be negative, a screening method with differing sensitivity
and specificity is far from ideal.
Predetermined antibody specificities allow virtual crossmatching to
be performed as soon as the donor candidate has been typed for HLA. A
virtual crossmatch performed with single antigen beads correlates with
the graft outcome, but the correlation with a physical crossmatch is
often not optimal due to differences in assays [5–7].
The predictive value of HLA antibodies identified with single an-
tigen beads differs for each crossmatch method. Since FCXM, similarly
to the routine bead array technique, identifies also non-complement-
binding antibodies, it could be expected to produce more concordant
results than Complement-dependent cytotoxicity crossmatch (CDCXM).
However, false positive FCXM results are regularly seen and the
crossmatch is not HLA-specific either [6]. One of the most recent
crossmatch methods is a solid phase method where donor HLA mole-
cules are captured on beads and analysed with a bead array. This
method, LXM, is one of two HLA-specific crossmatch methods available,
and it should correlate well with a virtual crossmatch [8]. The other
available donor specific crossmatch, which is not evaluated in this
study, is based on enzyme-linked immunosorbent assay [9].
2. Objective
Clinical laboratories working with organ transplantation struggle
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with the fact that antibody screening and the various crossmatching
techniques differ greatly in terms of their sensitivity. The aim of this
study was to compare the predictive value of the virtual crossmatch
with various crossmatch techniques used in clinical laboratory settings
and to identify the cut-off values with the best predictability.
3. Materials and methods
3.1. Sample collection
A total of 288 serum samples from 235 patients were used in
crossmatching (the latest serum of each patient was used). Samples
were stored frozen at −20 °C. Crossmatching with different techniques
was performed against splenocytes of 40 deceased donor candidates.
For CDCXM, freshly separated cells were used. For the other cross-
matching assays, splenocytes stored in liquid nitrogen were used.
3.2. Donor HLA typing
Donors were HLA typed with the complement-mediated lympho-
cytotoxicity test (Biotest Rockaway, NJ) and a low-resolution poly-
merase chain reaction with sequence-specific primers (One Lambda
Inc., Canoga Park, CA). Supplementary typing for HLA-A, B, C, DRB1-5,
DQA1, DQB1, DPA1 and DPB1 was performed with a polymerase chain
reaction with sequence-specific oligonucleotide probes (One Lambda)
when the result was needed to confirm the donor-specificity of an an-
tibody.
3.3. HLA antibody screening
Serum samples stored for routine crossmatching were used.
Antibodies were screened and identified with Luminex-based com-
mercial kits (LABScreen®, One Lambda) from untreated serum samples.
All specificities were identified with single antigen beads with a cut-off
value of the baseline normalized value 1000 MFI for an individual bead
representing a single DSA. All sera were tested for HLA class I (HLA-A,
-B and -Cw) and class II (HLA-DR, -DQ and -DP) antibodies. Antibodies
were assigned with the HLA Fusion™ software v.3.2. DSA was de-
termined by comparing assigned antibodies to the serological equiva-
lent of the donor's HLA type. For anti-DQ and –DP antibodies, α and β
chain combinations were used in the analysis. Known Finnish haplo-
types were utilised when a bead was selected to represent the antigen of
the donor [10]. MFI values of the donor-specific antibodies were re-
corded. The sum of all individual DSAs above 1000 MFI was reported as
the cumulative DSA [11,12].
3.4. Complement-dependent cytotoxicity crossmatch
CDCXM was performed during on-call with fresh density gradient-
purified donor spleen cells using the technique by Amos [13]. Cross-
matching was performed in parallel with various volumes of serum
(1 μl, 5 μl, 0.1 μl) as well as with an excess of complement (double
amount). Serum and cells were incubated 20 min at room temperature
and after complement addition 60 min at room temperature. Reactivity
was scored according to the percentage of dead cells with the interna-
tional workshop scoring: score 1:< 1%; 2: 1–20%; 4: 21–50%; 6:
51–80%; 8: 81–100%. As a local modification, any cell death above
background was considered positive (score 2). The highest reactivity of
parallel testing was used as the strength of an individual crossmatch in
further analysis. All crossmatches were performed without dithio-
threitol (DTT).
3.5. Flow cytometric crossmatch
FCXM was performed retrospectively with frozen donor splenocytes
[14]. T cell IgG and IgM and B cell IgG crossmatches were performed. In
each test, 500,000 splenocytes were incubated with 50 μl of serum for
30 min. After washing, T and B cells were identified with PE-anti-CD3
and PE-anti-CD19 (Cat no. 345765, 345777; BD Biosciences, San Jose,
CA). The secondary antibody was a FITC-conjugated F(ab)2 anti-human
IgG (Cat no. 109-096-098 Jackson ImmunoResearch, West Grove, PA).
After addition of fluorescence-labelled antibodies, cells were incubated
for 15 min in the dark. Cells were analysed using FACScan instrument
(BD Biosciences). A linear channel shift of at least 40 channels for T
cells and 60 channels for B cells was considered positive.
3.6. Luminex crossmatch
LXM with Tepnel Donor specific antibody kit (currently Immucor
Lifecodes) was performed retrospectively according to the manufac-
turer's protocol except for frozen splenocytes. Cells were thawed and
washed to remove dimethyl sulfoxide and then lysed. For each test, a
lysate containing 2.2 × 106 splenocytes was prepared. The lysate (8 μl)
was then incubated with 5 μl of capture beads coated with either anti-
HLA class I or class II for 30 min in the dark at room temperature. These
beads with captured donor HLA molecules where then incubated with
12 μl of the patient serum for 30 min at room temperature in the dark.
Binding of anti-HLA antibodies was detected with anti-human IgG
conjugated with PE (R-phycoerythrin). Samples were run on LabScan
200 and analysed with the LifeMatch software (Tepnel, Lifecodes). A
positive control bead (IgG) was used to verify the binding of anti-IgG-
PE. Three negative control beads were included and MFI values above
1000 against all three negative control values were considered positive.
3.7. Statistical analysis
Categorical variables were analysed with the Fisher's exact test. In
the ROC analysis, also DSA values below 1000 MFI were included as the
analysis was used to determine the best cut-off value. The sensitivity
and specificity of the various crossmatching methods were assessed
with the ROC analysis. The accuracy of the test was classified as the
AUC with 0.9–1: excellent; 0.8–0.9: good; 0.7–0.8: fair; 0.6–0.07: poor;
0.5–0.06: fail. Results with a P value of ≤0.05 were considered sta-
tistically significant. Analyses were performed with the SPSS statistics
version 21.0 software (IBM, Armonk, NY, USA).
4. Results
4.1. HLA antibody profile
Of the 364 crossmatches performed, the majority (68% (246)) were
performed with serum without HLA antibodies. Only 23% (83) of the
crossmatches were performed against DSA. The mean cumulative DSA
in DSA-positive crossmatches was 25,000 ± 23,000 MFI, with the
highest identified value being 90,000 MFI. Class I DSA was detected in
10% (37) and class II DSA in 5% (17) of the crossmatches, while both
class I and II DSA were detected in 8% (29) of the crossmatches.
Antibodies were most commonly directed against donor HLA-B antigens
(13% (48)) and least frequently against HLA-DRB3–5 (5% (17)) and
HLA-DP (5% (17)) (Fig. 1).
4.2. Complement-dependent cytotoxicity crossmatches
Crossmatches were performed against donor splenocytes containing
both T and B cells showing expression of Class I and Class II HLA an-
tigens. A total of 30% (111/364) of the crossmatches were positive,
with the highest scores being 2 (26%), 4 (35%), 6 (17%) and 8 (22%).
DSA was present in only 50% (55/111) of the positive CDCXM
(Table 1). A total of 11% (28/253) of the negative crossmatches were
performed against DSA. The score for cell death in CDCXM correlated
well with the degree of DSA positivity: for positive crossmatches with
weak positivity (score 2) only 31% of the crossmatches were against
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DSA, while for strong positives (score 8), 79% of the crossmatches were
against DSA. The total false positive and false negative rates for CDCXM
with a routine cut-off (score 2) were 20% (56/281) and 34% (28/83),
respectively. When the cut-off was elevated to score 4, the total false
positive and false negative rates were 13% (36/281) and 45% (37/83),
respectively.
4.3. Flow cytometric crossmatch performance
Separate crossmatches were performed on T and B cells in FCXM.
Positivity was seen in 27% (97/364) of the crossmatches (Table 1). The
total true positive rate for FCXM was 83% (69/83). In contrast, only 7%
(19/275) of the negative crossmatches were performed against DSA.
The total false positive and false negative rates were 10% (28/281) and
17% (14/83), respectively. T cells express only class I antigens, thus the
T cell crossmatch was compared to the class I DSA status. With T cells,
78% (29/37) of the crossmatches performed only against class I DSA
were positive. For Class II, the B cell crossmatch was comparable, with
76% (13/17) of the samples with only Class II DSA being positive. In-
terestingly, even with the higher class I expression in the splenic B cells,
the B cell crossmatch did not perform better in Class I DSA detection
than the T cell crossmatch (68% vs 78% (p = 0.4328) Table 1).
4.4. Luminex crossmatch performance
With LXM, it was possible to make separate crossmatches against
HLA class I and class II antigens. In total, 71% (59/83) of the cross-
matches performed against DSA were positive (Table 1). The total false
positive rate for LXM was 11% (31/281), while the false negative rate
was 29% (24/83). The LXM test was able to distinguish between posi-
tive crossmatches due to class I and class II. For crossmatches with ei-
ther class I or class II DSA only, the detection rate was 62% (23/37) and
65% (11/17) respectively, while false positive rate was only seen in 5%
(15/298) of the class I and 7% (22/318) of the class II crossmatches.
4.5. Accuracy of different crossmatch techniques
The accuracy of CDCXM in the identification of DSA at different
cumulative MFI values was evaluated with ROC analysis. The sensi-
tivity and specificity of different thresholds for CDCXM positivity are
shown in Fig. 2A. The predictive accuracy of the test was fair (AUC:
0.724) when the routine threshold for positivity (score 2) was used.
However, increasing the threshold of CDCXM to 4, 6 or 8 significantly
improved the predictive accuracy from fair to good, with AUC being
0.748, 0.802 and 0.855, respectively.
The performance of FCXM in the identification of any DSA (class I
and/or class II) was good (AUC: 0.861) (Fig. 2B). Nearly equal perfor-
mance was achieved with LXM (AUC: 0.805) (Fig. 2C).
4.6. Crossmatching and separation of class I and II DSA
A comparison of ROC analysis results for FCXM and LXM was per-
formed as these are the only methods with the capacity to distinguish
between crossmatches due to class I and class II antibodies. The lim-
itation with CDCXM is that it is performed with splenocytes containing
a mix of T and B cells. T cell FCXM and LXM showed similar diagnostic
performance for class I DSA, with AUCs of 0.853 and 0.837, respec-
tively (Fig. 2D). For class II DSA, both B cell FCXM and LXM reached a
fair performance result as their AUC values were 0.740 and 0.775, re-
spectively (Fig. 2E).
4.7. Sensitivity and specificity according to DSA level

















Fig. 1. Prevalence of DSAs directed against different HLA
antigens in crossmatches. HLA, human leukocyte antigen;
DSA, donor-specific antibody.
Table 1
Positive crossmatch results with different techniques and correlation with DSA
DSA− (n = 281) DSA+ (n = 83) Only Class I DSA (n = 37) Only Class II DSA (n = 17) Class I and II DSA (n = 29)
n % n % n % n % n %
CDCXM* 56 20 55 66 21 57 10 59 24 83
T-cell FCXM 20 7 61 73 29 78 7 41 25 86
B-cell FCXM 25 9 64 77 25 68 13 76 26 90
Total FCXM 28 10 69 83 29 78 13 76 27 93
Class I LXM 13 5 41 49 23 62 2 12 16 55
Class II LXM 20 7 30 36 2 5 11 65 17 59
Total LXM 31 11 59 71 23 62 11 65 25 86
The best detection rate in each DSA category is highlighted. *Threshold score ≥ 2. CDCXM, Complement-dependent cytotoxicity crossmatch; DSA, donor-specific antibody; FCXM, Flow
cytometric crossmatch; LXM, Luminex crossmatch.







Fig. 2. ROC curve analysis of DSA in comparison with
different crossmatch methods (A) DSA in comparison with
different thresholds for CDCXM. Threshold 2: AUC 0.724;
4: AUC 0.748; 6: AUC 0.802; 8: AUC 0.855. (B) DSA in
comparison with FCXM. AUC 0.861. (C) DSA in compar-
ison with LXM. AUC 0.805. (D) HLA Class I DSA in
comparison with FCXM and LXM AUC 0.853 and AUC
0.837, respectively. (E) HLA Class II DSA in comparison
with FCXM and LXM AUC 0.740 and 0.775, respectively.
AUC ≥ 0.8 was considered to constitute good accuracy
for the test. The linear part represents repeated identical
MFI values (no DSA identified). AUC, area under curve;
CDCXM, Complement-dependent cytotoxicity crossmatch;
DSA, donor-specific antibody; FCXM, Flow cytometric
crossmatch; LXM, Luminex crossmatch; MFI, mean
fluorescence intensity; ROC, receiver operating char-
acteristic.
Table 2
Cumulative DSA MFI cut-off values and sensitivity, specificity and accuracy of different crossmatch assays
Cumulative MFI cut-off n CDCXM FCXM LXM
Sensitivity Specificity Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity Accuracy
1000 83 0.495 0.803 0.769 0.722 0.940 0.885 0.667 0.905 0.849
5000 69 0.441 0.850 0.775 0.639 0.970 0.885 0.600 0.942 0.860
10,000 51 0.369 0.891 0.764 0.536 0.993 0.863 0.533 0.978 0.865
30,000 27 0.225 0.950 0.753 0.278 0.996 0.802 0.300 0.996 0.821
CDCXM, complement-dependent cytotoxicity crossmatch; DSA, donor specific antibodies; FCXM, flow cytometry crossmatch; LXM, Luminex crossmatch; MFI, mean fluorescence in-
tensity.
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method is shown in Table 2. The highest sensitivity in the identification
of DSA can be reached with a cut-off of 1000 MFI with FCXM (0.722).
Almost similar results can be obtained with LXM (0.667). The sensi-
tivity of the assays rapidly decreases as the cut-off for the cumulative
DSA increases. The specificity of the methods proved to be good. When
the cumulative DSA MFI cut-off was adjusted, only a moderate effect on
specificity was seen.
The cut-off resulting in the highest accuracy (the rate of true ne-
gative and true positive values) was different for each method. For
FCXM, the best accuracy was achieved with both 1000 and 5000 MFI
and for CDCXM with 5000 MFI, while LXM showed the highest accu-
racy with a cut-off of 10,000 MFI. The results of individual samples
with each crossmatch method shows the concordance between the
methods. From the crossmatches where DSA was present, only 6% (5/
83) were false negatives with all methods (Fig. 3A). However, most
samples giving false positive results are different with each method
(Fig. 3B).
5. Discussion
In this study, we compared a virtual crossmatch performed with
single antigen beads to various crossmatch methods typically used in
clinical laboratories serving organ transplant programs. The solid phase
assay with single antigen beads has been proven to be sensitive and
accurate in screening and identifying HLA antibodies. The drawback for
the bead array is that it does not measure exactly the same variable as
the crossmatch methods used routinely.
From the 83 crossmatches performed against DSA, the best perfor-
mance was observed with FCXM (83%). With LXM and CDCXM, the
DSA detection rates were 71% and 66%, respectively. The lower per-
formance of CDCXM in detecting DSA is caused by lack of sensitivity
[15]. This is partially due to the measurement of only antibodies cap-
able of complement-dependent lymphocyte killing. In our study, the
detection rate of 66% for DSA achieved with CDCXM is higher than
reported in a recent study where the detection rate was 48% for T cells
and 38% for B cells [16]. Also, the DSA detection rate of 83% with
FCXM was higher than seen in previous studies in which the rates
ranged from 52 to 65% [17,18]. In our study, the better DSA detection
rate could be explained by the fact that splenocytes were used as a
source for donor cells. It is known that the density of HLA molecules
especially in the B cell population from the spleen is higher than in
blood-derived cells [19].
With the default cut-off of 1000 MFI for DSA, the highest false po-
sitive rate was seen for CDCXM (20%). FCXM and LXM produced more
accurate results (10% and 11%, respectively). Based on our findings
there is only a minor overlap on samples producing false negative and
positive results between the methods. This indicates that the difference
seen between the methods is based on the type of antibodies detected
rather than the cut-off used in each technique. The high rate of false
positives from CDCXM performed with a mixed T and B cell population
is in line with a previous study where false positive rates of 18% and
23% were detected for T and B cells, respectively [16]. The false
positive rate with the cytotoxic B cell crossmatch is known to be par-
ticularly high [20]. In our study, the higher number of false positives
may be explained by IgM antibodies or autoantibodies as no DTT was
used to neutralize these antibodies. In this study, 36% (20/56) of the
false positive CDCXMs were also positive for T cell IgM FCXM (data not
shown). If this is taken into account, the rate for false positives would
only be 13% (36/281) and the remainder of the false positives (7% (20/
281)) could be explained by IgM antibodies. Further, the prozone effect
known to affect bead array technique may give false negative results as
EDTA treatment was not used [21]. Therefore, some DSAs may have
been missed. However, in our experience this phenomenon is rare in
patients on transplant waiting list, yet it is seen more commonly in
patients with immunopathological status.
The sensitivity and specificity of a crossmatch method depends
largely on the cut-off value selected. It has been widely accepted that
the sensitivity of FCXM is much better than that of CDCXM [22].
However, by adjusting the cut-off to avoid false positives, it is possible
to decrease the sensitivity of a method even though the technique itself
could perform better. In a clinical laboratory, the cut-off value needs to
be adjusted to the consensus level defined by external proficiency
testing. Further, the cut-off used must provide results with diagnostic
value.
In organ transplantation, with a limited number of transplants, the
tolerance for false negatives is low. Typically, laboratories aim at higher
sensitivity at the expense of specificity in an effort to avoid hyperacute
rejection and laborious treatment of antibody-mediated rejection. On
the other hand, false positive crossmatches or crossmatches that are too
sensitive prevent transplants with an acceptable outcome. We face this
issue with the LXM technique as it is a new method and there is lack of
experience in laboratory routine.
In our hands, the default cut-off for LXM was found to be too low
because an unacceptably high number of false positives was detected.
Thus, a laboratory-specific cut-off value was determined. However, this
is based on a limited sample number and it may not be the most op-
timal. With the new cut-off, the method has the capability to separate
crossmatch positivity due to class I and class II antibodies. Based on our
results, it seems to be impossible to draw conclusions on class I or II
positivity using T and B cell crossmatches only. Thus, T and B cell
crossmatches are not equivalent for class I and II crossmatches. At
0.667, the overall sensitivity of LXM was lower than reported earlier
(0.96 for class I and 0.65 for class II) but the specificity of 0.905 was in
line with that seen in previous studies (1.0 for class I and 0.97 for class
II) [8]. Previous studies suggests that capture of DQ and DP molecules is
impaired in the LXM method [8,23]. We were unable to confirm this
finding as the number of samples with DSA against one loci only was
very low as our samples were not selected to answer that question.
Methods for detecting HLA class-specific antigens are scarce as most
techniques detect any foreign antigens. However, LXM provides HLA-
specificity as only donor HLA antigens are bound to the beads.
Generally, an AUC ≥ 0.8 is considered to constitute a good test. If
false negative results are considered detrimental, lower cut-off values
producing fewer false negatives will not result in an AUC level required
A B Fig. 3. Crossmatch-positivity of individual samples witheach technique. (A) Crossmatches of DSA-positive samples.
(B) Crossmatches of DSA-negative samples.
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of a good test, as was evident with CDCXM. When the cut-off value was
changed from score 2 to 8, the accuracy of the test improved (AUC:
0.724–0.855). This result is in line with the findings of Wahrmann et al.
[12] where similar results were obtained for class I and II separately.
The sensitivity of the crossmatch assays rapidly decreased when the
cut-off for virtual crossmatch positivity was increased (table 2). How-
ever, the process is always a trade-off between sensitivity and specifi-
city. If we use accuracy (rate of true positives and true negatives) as a
standard for setting the cut-off value for the crossmatch techniques, a
different cut-off should be set for each technique. With FCXM, the best
accuracy was reached with cut-offs 1000 MFI and 5000 MFI while for
CDCXM, the best accuracy was reached with the cut-off of 5000 MFI.
For LXM, the cut-off value of 10,000 MFI was found to be the most
optimal. However, the impact of the cut-off on accuracy was marginal,
with a clear difference only seen for FCXM.
As long as routine screening methods identify antibodies based on
their capacity to bind known targets it is practically impossible to detect
the complete antibody repertoire of an individual serum. HLA class II
antibodies present the greatest challenges as their targets are formed by
alfa and beta chains produced by different genes. We have very little
knowledge of the types of class II hybrid molecules that exist (e.g.
DQA1 + DPB1) and of their relative proportions on donor cells. The
target cells in CDCXM express also non-HLA antigens interfering with
the test. Consequently, the virtual crossmatch is not equal to an actual
crossmatch in performance.
Yet another limitation of the virtual crossmatch is the biological
nature of the crossmatch and the unpredictability of the donor material.
In a recent study by Badders et al. [19], it was shown that there is a
broad variation in HLA expression between donors (for T cells from
PBLs 455 ± 160 molecules of equivalent soluble fluorochromes). Also,
extensive variation was seen between different cell sources (blood,
spleen, node). Variation in HLA expression levels had a direct impact on
the FCXM reactivity [19]. An antibody screening technique can be
standardized but the density of HLA on the target cells cannot. There-
fore, there will always be uncertainty unless HLA expression levels are
assessed at the time of the crossmatch. The only crossmatch methods
that permit the standardization of the amount of donor HLA are the
methods in which donor antigens are captured onto a solid phase [8,9].
5.1. Limitations
Some limitations apply to this study. The work could have been
strengthened by correlation to clinical data. However, clinical data was
not available for this study. In addition, only a small portion of the
crossmatches resulted in transplantation, therefore a methodological
approach was chosen. In CDCXM, only total lymphocytes were used in
accordance with the national transplant protocol, thus no separate re-
sult for T and B cells were available. Also, the lack of DTT treatment
results raises the false positive rate in CDCXM and hampers the com-
parability to results obtained by other laboratories.
6. Conclusions
To conclude, the best correlation was observed between the virtual
crossmatch and FCXM, with LXM performing almost as well. This
method seems particularly promising as it permits the standardization
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